Prime Capital Investment Advisors LLC Purchases 46 Shares of Cencora, Inc. (NYSE:COR)

Prime Capital Investment Advisors LLC raised its position in shares of Cencora, Inc. (NYSE:COR) by 1.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,768 shares of the company’s stock after buying an additional 46 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Cencora were worth $848,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in COR. New Millennium Group LLC bought a new stake in shares of Cencora in the second quarter worth about $26,000. TFO Wealth Partners LLC purchased a new position in shares of Cencora during the first quarter valued at approximately $30,000. LRI Investments LLC bought a new position in shares of Cencora during the first quarter valued at approximately $31,000. MFA Wealth Advisors LLC purchased a new stake in Cencora in the second quarter worth $30,000. Finally, Concord Wealth Partners bought a new stake in Cencora in the third quarter valued at $30,000. Institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

COR opened at $240.24 on Friday. The firm has a market cap of $47.34 billion, a PE ratio of 31.99, a P/E/G ratio of 1.66 and a beta of 0.44. The stock has a 50-day moving average price of $232.62 and a 200-day moving average price of $231.08. Cencora, Inc. has a 1 year low of $194.23 and a 1 year high of $251.56. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.92%. The ex-dividend date of this dividend is Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is currently 29.29%.

Analysts Set New Price Targets

COR has been the subject of several research reports. Evercore ISI upped their price objective on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Barclays lifted their price objective on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Wells Fargo & Company increased their target price on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Bank of America restated a “neutral” rating and set a $245.00 price target (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Finally, Robert W. Baird raised their price objective on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $271.20.

Insider Activity

In related news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This trade represents a 7.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 15.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.